» Articles » PMID: 17116308

Ligand-regulated Peptide Aptamers That Inhibit the 5'-AMP-activated Protein Kinase

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2006 Nov 23
PMID 17116308
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

In an effort to extend the peptide aptamer approach, we have developed a scaffold protein that allows small molecule ligand control over the presentation of a peptide aptamer. This scaffold, a fusion of three protein domains, FKBP12, FRB, and GST, presents a peptide linker region for target protein binding only in the absence of the small molecule Rapamycin or other non-immunosuppressive Rapamycin derivatives. Here we describe the characterization of ligand-regulated peptide aptamers that interact with and inhibit the 5'-AMP-activated protein kinase (AMPK). AMPK, a central regulator of cellular energy homeostasis, responds to high cellular AMP/ATP ratios by promoting energy producing pathways and inhibiting energy consuming biosynthetic pathways. We have characterized 15 LiRPs of similar, poly-basic sequence and have determined that they interact with the substrate peptide binding region of both AMPK alpha1 and alpha2. These proteins, some of which serve as poor substrates of AMPK, inhibit the kinase as pseudosubstrates in a Rapamycin-regulated fashion in vitro, an effect that is largely competitive with substrate peptide and mediated by an increase in the kinase's apparent K(m) for substrate peptide. This pseudosubstrate inhibition of AMPK by LiRP proteins reduced the AMP stimulation of AMPK in vitro and caused the inhibited state of the kinase to kinetically resemble the basal, unstimulated state of AMPK, providing potential insight into the molecular mechanisms of AMP stimulation of AMPK.

Citing Articles

Synthetic biology for pharmaceutical drug discovery.

Trosset J, Carbonell P Drug Des Devel Ther. 2015; 9:6285-302.

PMID: 26673570 PMC: 4675648. DOI: 10.2147/DDDT.S58049.


Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling.

Conidi A, van den Berghe V, Huylebroeck D Int J Mol Sci. 2013; 14(4):6690-719.

PMID: 23531534 PMC: 3645661. DOI: 10.3390/ijms14046690.


Development and application of in vivo molecular traps reveals that dynein light chain occupancy differentially affects dynein-mediated processes.

Varma D, Dawn A, Ghosh-Roy A, Weil S, Ori-McKenney K, Zhao Y Proc Natl Acad Sci U S A. 2010; 107(8):3493-8.

PMID: 20133681 PMC: 2840451. DOI: 10.1073/pnas.0908959107.

References
1.
Choi J, Chen J, Schreiber S, Clardy J . Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996; 273(5272):239-42. DOI: 10.1126/science.273.5272.239. View

2.
. Finishing the euchromatic sequence of the human genome. Nature. 2004; 431(7011):931-45. DOI: 10.1038/nature03001. View

3.
Liberles S, Diver S, Austin D, Schreiber S . Inducible gene expression and protein translocation using nontoxic ligands identified by a mammalian three-hybrid screen. Proc Natl Acad Sci U S A. 1997; 94(15):7825-30. PMC: 21513. DOI: 10.1073/pnas.94.15.7825. View

4.
McCafferty D, Lessard I, WALSH C . Mutational analysis of potential zinc-binding residues in the active site of the enterococcal D-Ala-D-Ala dipeptidase VanX. Biochemistry. 1997; 36(34):10498-505. DOI: 10.1021/bi970543u. View

5.
Abedi M, Caponigro G, Kamb A . Green fluorescent protein as a scaffold for intracellular presentation of peptides. Nucleic Acids Res. 1998; 26(2):623-30. PMC: 147301. DOI: 10.1093/nar/26.2.623. View